Abstract:Introduction Cardiomyopathy causes ∼12.1% of pregnancy-related maternal mortality. Dilated cardiomyopathy(DCMP) in pregnancy is often either already known or discovered in the 2nd trimester as hemodynamic changes begin. Management is challenging as guideline directed medical therapy for heart failure with reduced ejection fraction is contraindicated in pregnancy. Antepartum cardiogenic shock(reported incidence ∼17%) significantly worsens outcomes. We describe using an Impella 5.5 micro-axial pump to successfully support a pregnancy complicated by DCMP and cardiogenic shock(CS). Clinical Case A 27-year-old gravida 3, parity 2 presented with CS in week 24 of pregnancy. Symptoms manifested around week 16 and progressively worsened. She was orthopneic and had anasarca. Lactic acid at presentation was 7.5mmol/L. Labs were otherwise unremarkable. Right heart catheterization revealed RA pressure of 15mmHg, PA pressure of 64/36mmHg (mean 45mmHg), cardiac index of 1.6L/min/m2 and systemic vascular resistance >1300 dyne/cm5. PCWP could not be measured due to severe PA dilation. Echocardiogram revealed biventricular dilation with an LVEF<20%, LVEDd 7.8cm & severe mitral regurgitation. She was initiated on dobutamine but transitioned to milrinone for more effective vasodilation. She received aggressive diuresis. Anasarca improved but elevated PA pressures persisted. Fetal monitoring was performed by the maternal-fetal medicine/obstetric team. Due to her critical condition and body habitus, assessing fetal growth accurately was challenging although there was restricted growth at baseline. Cardiac index improved modestly and a decision was made to escalate support to an axillary Impella 5.5 to augment flow to the mother and, hopefully, placental flow to the fetus. She underwent a successful cesarean delivery 4 weeks after Impella placement. The Impella remained for 3 weeks post-partum hoping for ventricular recovery. Hope unrealized, she underwent an HM3 LVAD placement. Cardiac biopsy at that time showed disarrayed hypertrophic cardiomyocytes without interstitial fibrosis or infarction. She remains independent and functional at follow-up. Her daughter is home after 3 months in the NICU. Discussion Impella is a percutaneous LVAD used to support patients with CS. Its use in pregnancy is rare and safety data in this population is limited. Pregnancy in patients with DCMP is potentially dangerous given the increased demands on the cardiovascular system. Treating CS in pregnancy is complex and requires a multidisciplinary approach. Conventionally, options were early delivery or termination. There have been few case reports describing Impella use in pregnancy with CS. To our knowledge this is the first reported case using an axillary Impella 5.5 to support a patient for several weeks to achieve cardiac stability as well as allow fetal maturity. The axillary placement of the Impella 5.5 also helped the patient maintain ambulation. Using an Impella in pregnancy requires careful consideration of potential risks and benefits for mother and fetus, and close monitoring by a multidisciplinary team.

Cardiogenic Shock and Utilization of Mechanical Circulatory Support in Pregnancy

Mechanical circulatory support for cardiogenic shock during the peripartum period

Cardiac physiology and pathophysiology in pregnancy

One Pump for Two Hearts: Using an Impella 5.5 Micro-Axial Pump in Peripartum Cardiogenic Shock

Ischemic heart disease in pregnancy: a practical approach to management

Pulmonary Hypertension and Pregnancy Outcomes: Insights From the National Inpatient Sample

Cardiomyopathies in Pregnancy: Trends and Clinical Outcomes in Delivery Hospitalizations in the United States (2005-2020)

Pregnancy in women with congenital heart disease: a focus on management and preventing the risk of complications

Cardiovascular determinants of impaired placental function in women with cardiac dysfunction

Creating a Multidisciplinary Pregnancy Heart Team

Universal Cardiovascular Disease Risk Assessment in Pregnancy: Call to Action JACC: Advances Expert Panel

Adverse Pregnancy Conditions Among Privately Insured Women With and Without Congenital Heart Defects

Maternal heart failure: state-of-the-art review

Preliminary data on short-term outcomes within the cardio-obstetrics registry

One Pump For Two Hearts - A Single-center Experience With An Impella 5.5 Micro-axial Pump In A Peripartum Patient With Cardiogenic Shock

Abstract 13230: Prevalence, Trends, and Outcomes of Cardiovascular Diseases in Pregnant Patients in the United States: 2010 to 2019

A Practical Approach to the Diagnosis and Initial Management of Acute Right Ventricular Failure during Pregnancy using Point-of-Care Ultrasound

Abstract 4127345: National Cohort Study on Hypertensive Disorders of Pregnancy among Women with Congenital Heart Disease: Insights from Multiple Centers

Maternal And Fetal Outcomes In Patients With Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy In Pregnancy: A Retrospective Study Of Patients Characteristics And Outcomes

Adult Congenital Heart Disease with Pregnancy